Enzalutamide: A new prostate cancer targeted therapy against the androgen receptor - Abstract

Enzalutamide (MDV3100), an androgen receptor-signalling inhibitor, represents the most recent compound added to the therapeutic armamentarium for the treatment of metastatic castration-resistant prostate cancer (mCRPC) who progressed to docetaxel.

The anti-tumour activity and safety of enzalutamide has been demonstrated in a phase III clinical trial, showing a benefit in overall survival, which was the primary endpoint. There are no head-to-head studies comparing the different treatment options in this subset of patients. In this article, most relevant data published in the literature have been reviewed, with special attention to the therapeutic alternatives currently available for postdocexatel mCRPC patients, emphasising the mechanisms of action of the different drugs, efficacy and quality of life-related aspects.

Written by:
Quintela ML, Mateos LL, Estévez SV, Calvo OF, Herranz UA, Afonso FJ, Santomé L, Aparicio LA.   Are you the author?
Oncología Médica, Complexo Hospitalario Universitario de Vigo, C/Pizarro 22, 36204 Vigo, Spain; Servicio de Oncología Médica, Complexo Hospitalario Universitario de Pontevedra, Spain; Servicio de Oncología Médica, Hospital Universitario Lucus Augusti, C/Doutor Ulises Romero, s/n, 27003 Lugo, Spain; Servicio Oncologia Medica, Complejo Hospitalario Universitario Ourense, C/Ramón Puga 54.32005, Spain; Oncología Médica, Complejo Hospitalario Universitario de Santiago de Compostela, c/Choupana s/n, 15706 Santiago de Compostela, A Coruña, Spain; Oncología Médica, C.H.U.Ferrol, Ferrol, A Coruña, Spain; Servicio de Oncología Médica, Hospital Povisa, C/Salamanca 5, 36211 Vigo, Spain; Medical Oncology Service, CHUA Coruña, Spain. ; ; ; ; ; ;

Reference: Cancer Treat Rev. 2015 Mar;41(3):247-253.
doi: 10.1016/j.ctrv.2014.12.006


PubMed Abstract
PMID: 25638257

UroToday.com mCRPC Treatment Section